Semaglutide
Semaglutide is Novo Nordisk’s GLP-1 receptor agonist — sold as Ozempic and Rybelsus for type 2 diabetes and Wegovy for weight management — the molecule that made GLP-1 a household term.
- Novo Nordisk’s GLP-1: Ozempic, Rybelsus, Wegovy
- Wegovy holds weight-management and cardiovascular indications
- Compounding moved to the patient-specific pathway as supply normalized
- Manufacturer cash-pay channels now anchor DTC pricing
One molecule, three brands
Ozempic (weekly injection) and Rybelsus (daily oral) carry the diabetes indications; Wegovy (weekly injection, higher dose range) carries the weight-management indication, later adding a cardiovascular risk-reduction indication that strengthened the case for insurance coverage. Clinicians may prescribe any of them off-label within their judgment, but marketing a program must track the actual indications.
The operational history that still shapes programs
Semaglutide’s demand explosion produced years of shortage, during which compounded semaglutide made weight care affordable at national scale. The shortage’s resolution in early 2025 closed that broad window and moved compounding to the patient-specific pathway, while Novo added direct-to-patient cash pricing through its own channels. Today’s programs source through branded channels, patient-specific compounding with documented clinical justification, or both — with clinicians matching each patient to the right product.
The three brands, side by side
| Brand | Indication | Form | Notes |
|---|---|---|---|
| Ozempic | Type 2 diabetes | Weekly injection | The household name; off-label weight use at clinician discretion |
| Rybelsus | Type 2 diabetes | Daily oral | The needle-free option |
| Wegovy | Weight management + CV risk reduction | Weekly injection | The on-label weight product — build programs here |
How programs source it now
Three channels coexist: manufacturer direct cash-pay (NovoCare-style pricing in the several-hundred-dollars-a-month range), insurance coverage where formularies and prior auth allow, and patient-specific compounding where a clinician documents an individualized need a commercial product doesn’t serve. Strong programs treat channel selection as part of the clinical workflow — the clinician matches each patient to product and channel, and the program’s pricing communicates all three paths honestly.
Compliance handled, so you can build
Lithos runs the clinicians, pharmacies, and 50-state rules behind your care program — one API.
Frequently asked questions
Can a telehealth program prescribe Ozempic for weight loss?
Off-label prescribing is a clinician’s judgment call, but programs should be built and marketed around the on-label product — Wegovy — for weight management.
Is compounded semaglutide still legal?
The patient-specific pathway continues — compounding supported by an individual patient’s documented clinical needs. Broad compounding of standard doses ended with the shortage, which is why documentation discipline now defines the category.
What does semaglutide cost cash-pay?
Manufacturer direct channels reset cash pricing to several hundred dollars a month, well below original list — exact figures move, so check current programs.